Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
- Conditions
- Bilateral Nasolabial Fold Wrinkles
- Interventions
- Biological: PlaceboBiological: Autologous Human Fibroblast (azficel-T)
- Registration Number
- NCT00649428
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Brief Summary
The purpose of this study is to evaluate the safety profile and the treatment effect of Isolagen TherapyTM compared with placebo when administered to bilateral nasolabial fold wrinkles.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 203
- Subject is at least 18 years of age
- Level of severity of bilateral nasolabial fold wrinkles meeting severity criteria as per protocol
- Level of subject dissatisfaction with both nasolabial fold wrinkles as per protocol
- Ability to comply with the study requirements
- Negative pregnancy test (Females)
- Healthy post-auricular skin for biopsy
- Excessive dermatochalasis of the treatment area
- Inability to lessen the nasolabial fold wrinkles by physically spreading the area apart
- Total area to be treated exceeds 20 cm in length
- Physical attributes which may prevent assessment or treatment as judged by the evaluator
- Use of an investigational product/procedure within 30 days prior to enrollment or plans for use during the study
- Previous treatment with the sponsor's product
- History of active autoimmune disease or organ transplantation
- Diagnosis of cancer, unless successfully treated or in remission (basal cell carcinoma is excluded)
- Active or chronic skin disease
- Known genetic disorders affecting fibroblasts or collagen
- Active systemic infection
- Requires chronic antibiotic or steroidal therapy
- Use of certain commercial products/procedures to the treatment area prior to study enrollment or plans for use during the study
- Use of systemic agents that increase bleeding or clotting, or disorders equated with these effects
- Known allergic reactions to agents used in preparation of treatment
- Excessive exposure to sun without adequate sun protection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Placebo - Active Autologous Human Fibroblast (azficel-T) -
- Primary Outcome Measures
Name Time Method Subject Wrinkle Assessment Responders Baseline (prior to first treatment) and 6 months post final treatment A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.
Evaluator Wrinkle Severity Assessment Responders Baseline (prior to first treatment) and 6 months after last treatment A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.
- Secondary Outcome Measures
Name Time Method Evaluator Wrinkle Severity Assessment Responders Baseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment A responder was defined as a two point improvement on the blinded Evaluator's live assessment of each of the bilateral nasolabial fold wrinkles at rest using the 6-point ordinal Lemperle Wrinkle Severity Scale. On the Lemperle scale, a score of 5 (Very Deep Wrinkle) is worst and a score of 0 (No Visible Wrinkle) is best.
Subject Wrinkle Assessment Responders Baseline (prior to first treatment) compared to 3rd treatment visit, 2 and 4 months post final treatment A two point improvement on the Subject's live assessment of the wrinkles of the lower part of the face as compared to baseline on the Subject Wrinkle Assessment was considered a responder. The Subject Wrinkle Assessment scale was a five point scale with a score of -2 (Very Dissatisfied) being the worst and a score of +2 (Very Satisfied) being the best.
Trial Locations
- Locations (7)
Silverburg Surgical & Medical Group
🇺🇸Newport Beach, California, United States
Dermatology Research Institute, LLC
🇺🇸Coral Gables, Florida, United States
Total Skin & Beauty Dermatology Center, PC
🇺🇸Birmingham, Alabama, United States
River North Dermatology and Dermatologic Surgery
🇺🇸Naperville, Illinois, United States
Dermatology, Laser & Vein Specialists of the Carolinas
🇺🇸Charlotte, North Carolina, United States
Center for Skin Research
🇺🇸Houston, Texas, United States
Aesthetic Solutions
🇺🇸Chapel Hill, North Carolina, United States